Form 4: Arcturus Therapeutics Director Magda Marquet Reports Stock Option Grant and Deferred Stock Unit Conversion

Director Magda Marquet reports the acquisition of stock options and conversion of deferred stock units into common stock at Arcturus Therapeutics Holdings Inc.

Summary

• On June 14, 2024, Magda Marquet, a director of Arcturus Therapeutics Holdings Inc., reported transactions involving the company's stock.
• Marquet converted 3,131 deferred stock units into 3,131 shares of common stock.
• Additionally, Marquet acquired 15,000 stock options with an exercise price of $31, vesting monthly over one year from the grant date of June 14, 2024, and expiring on June 14, 2034.
• Marquet also indirectly owns 24,942 shares of common stock via Alma Life Sciences, LLC.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating insider transactions. The acquisition of options could be seen as a slightly positive signal, but it's not a strong indicator.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future actions of key individuals within the company.

Comparison to Industry Standards

• Stock option grants to board members are a common practice in the biotechnology industry to align their interests with those of shareholders.
• The vesting schedule of the options (monthly over one year) is fairly standard.
• Comparing the size of the grant to those of directors at similar-sized biotech companies (e.g., Alnylam, Moderna) would provide further context on its significance.

Stakeholder Impact

• The transactions could have a minor impact on shareholders by slightly increasing the number of outstanding shares upon option exercise.

Key Dates